Dyadic International, Inc.

208 articles with Dyadic International, Inc.

• Dyadic to Report Second Quarter 2022 Financial Results on Wednesday, August 10, 2022

  7/27/2022

  Dyadic International, Inc. announced that it will report its financial results for the second quarter 2022 and host a corporate update conference call on Wednesday, August 10, 2022.

• Dyadic to Participate in Bio-Manufacturing Innovation Summit and NIIMBL National Meeting

  7/5/2022

  Dyadic International, Inc. today announced that its management and representatives will participate in the following two upcoming industry events in July 2022:

• Dyadic to Participate in Three Upcoming Industry Events in June 2022

  6/9/2022

  Dyadic International, Inc. announced that its management and representatives will participate in the following three upcoming industry events in June 2022:

• Dyadic to Present at 2022 Jefferies Healthcare Conference

  6/2/2022

  Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that its Chief Executive Officer, Mark Emalfarb will present at the 2022 Jefferies Healthcare Conference.

• Dyadic to Present at H.C. Wainwright Global Investment Conference

  5/20/2022

  Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI) a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and drugs at flexible commercial scales, today announced that the Company will participate in the 2022 H.C. Wainwright Global Investment Conference.

• Dyadic Reports First Quarter 2022 Financial Results and Highlights Recent Company Developments

  5/12/2022

  Dyadic International, Inc., a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics announced its financial results for the first quarter of 2022, and highlighted recent company developments.

• Dyadic to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

  4/28/2022

  Dyadic International, Inc. announced that it will report its financial results for the first quarter 2022 and host a corporate update conference call on Thursday, May 12, 2022.

• Epygen Biotech Announces Funding from India Government for Development of a COVID-19 Vaccine Using Dyadic’s Licensed C1 Protein Production Platform

  4/13/2022

  Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company announced today that Dyadic Licensee, Epygen Biotech PVD, LTD., has received funding from the Department of Biotechnology, Government of India, to advance an affordable COVID-19 vaccine candidate through Phase 1 and Phase 2 clinical trials in India which utilizes Dyadic’s C1 protein production platform.

• Dyadic International to Present at Upcoming Scientific Medical Meetings

  4/4/2022

  Dyadic International, Inc. today announced that its management and representatives will be presenting at the following scientific medical meetings.

• Dyadic Reports 2021 Year End Results and Recent Company Progress

  3/29/2022

  Dyadic International, Inc., a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics announced its financial results for year end 2021 and highlighted recent Company progress.

• Dyadic to Report 2021 Year-End Financial Results on Tuesday, March 29, 2022

  3/15/2022

  Dyadic International, Inc. announced that it will report its financial results for 2021 year-end and host a corporate update conference call on Tuesday, March 29, 2022.

• Dyadic and Phibro Animal Health Announce Exclusive License Agreement to Develop and Commercialize Animal Health Vaccine

  2/10/2022

  Dyadic International, Inc. and Phibro Animal Health jointly announced that they have entered into an exclusive license agreement for a Phibro targeted disease.

• Dyadic International’s CEO Mark Emalfarb to Present at BIO CEO & Investor Conference

  2/7/2022

  Dyadic International, Inc. announced that the Company’s CEO Mark Emalfarb will be presenting at the upcoming 2022 BIO CEO & Investor Conference being held at the Marriott Marquis New York City February 14th -15th, and virtually through the 17th.

• Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform

  12/17/2021

  Dyadic International, Inc. announced that it has entered into a Research, License and Collaboration Agreement (“Agreement”) with Janssen Biotech, Inc. (‘’Janssen”), one of the Janssen Pharmaceutical Companies of Johnson & Johnson.

• Dyadic Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

  11/10/2021

  Dyadic International, Inc., a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics announced its financial results for the third quarter of 2021, and highlighted recent Company progress.

• Dyadic Appoints Chief Business Officer to Executive Leadership Team

  11/9/2021

  Dyadic International, Inc., a global biotechnology company focused on further improving, applying and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines, therapeutics and other protein based products announced the appointment of Joe Hazelton as Chief Business Officer, effective immediately.

• Dyadic to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

  10/27/2021

  Dyadic International, Inc. today announced that it will report its financial results for the third quarter ended September 30, 2021 and host a corporate update conference call on Wednesday, November 10, 2021.

• Dyadic to Present at H.C. Wainwright 23rd Annual Global Investment Conference

  9/10/2021

  Dyadic International, Inc. today announced that the Company’s management will be attending and presenting at the following upcoming virtual investor event: Date: Monday, September 13, 2021 Time: 7:00 AM Eastern Time –

• Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

  8/12/2021

  Dyadic International, Inc., a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics announced its financial results for the second quarter of 2021 and highlighted recent Company progress.

• Dyadic and Sorrento Announce Binding Term Sheet to License Dyadic’s Lead COVID-19 Vaccine Candidate “DYAI-100” and C1 Technology for Protein-Based Coronavirus Vaccines and Therapeutics

  8/11/2021

  Dyadic today announced the signing of a binding term sheet to enter into a License Agreement to develop and commercialize vaccines, therapeutics, and diagnostics for coronaviruses, including Dyadic’s lead COVID-19 vaccine candidate, DYAI-100.